Neovasc Inc to Post Q4 2020 Earnings of $0.01 Per Share, Svb Leerink Forecasts (NVCN)

Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) – Analysts at Svb Leerink issued their Q4 2020 EPS estimates for shares of Neovasc in a research note issued on Friday, April 12th. Svb Leerink analyst D. Antalffy expects that the medical equipment provider will earn $0.01 per share for the quarter.

Neovasc (NASDAQ:NVCN) (TSE:NVC) last released its earnings results on Thursday, March 21st. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). The business had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.60 million.

NVCN has been the subject of a number of other research reports. ValuEngine raised shares of Neovasc from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research lowered shares of Neovasc from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th.

Neovasc stock opened at $0.41 on Monday. The firm has a market cap of $25.17 million, a price-to-earnings ratio of -0.15 and a beta of 1.59. Neovasc has a fifty-two week low of $0.37 and a fifty-two week high of $5.20.

A hedge fund recently bought a new stake in Neovasc stock. Virtu Financial LLC acquired a new position in shares of Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 63,055 shares of the medical equipment provider’s stock, valued at approximately $38,000. Virtu Financial LLC owned 0.27% of Neovasc as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 4.64% of the company’s stock.

About Neovasc

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

Further Reading: Yield Curve

Earnings History and Estimates for Neovasc (NASDAQ:NVCN)

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit